Similar articles

• The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis.

  Kaul R, Shenoy M, Christadoss P. Kaul R, et al. Adv Neuroimmunol. 1994;4(4):387-402. doi: 10.1016/0960-5428(94)00012-d. Adv Neuroimmunol. 1994. PMID: 7536602 Review. No abstract available.
• Immunogenetics of experimental autoimmune myasthenia gravis.

  Christadoss P. Christadoss P. Crit Rev Immunol. 1989;9(4):247-78. Crit Rev Immunol. 1989. PMID: 2679661 Review.
• Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis.

  Kaul R, Shenoy M, Goluszko E, Christadoss P. Kaul R, et al. J Immunol. 1994 Mar 15;152(6):3152-7. J Immunol. 1994. PMID: 8144909
• Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors.

  Christadoss P, Lennon VA, Krco CJ, David CS. Christadoss P, et al. J Immunol. 1982 Mar;128(3):1141-4. J Immunol. 1982. PMID: 6799570
• Molecular immunopathogenesis of myasthenia gravis using MHC class II mutant and transgenic mice.

  Shenoy M, David C, Oshima M, Atassi MZ, Christadoss P. Shenoy M, et al. Ann N Y Acad Sci. 1993 Jun 21;681:329-31. doi: 10.1111/j.1749-6632.1993.tb22909.x. Ann N Y Acad Sci. 1993. PMID: 8395148 No abstract available.